New brain chemical pump is “huge step forward” for advanced Parkinson’s

Advances

Author: Parkinson's Life editorsPublished: 9 April 2015

Parkinson's LifePrep: Parkinson's LifeCook: Parkinson's LifeServes:

DUOPA pump

Campaigners in the US have welcomed the approval of a new dopamine pump as “a huge step forward” for treatment of people with advanced Parkinson’s disease.

Responding to news that the US Food and Drug Administration had approved DUOPA – a portable infusion pump that delivers carbidopa and levodopa directly into the small intestine – NPF national medical director Dr Michael S. Okun said: “The approval of the dopamine pump for the treatment of Parkinson’s disease is a huge step forward for treatment of Parkinson’s disease patients suffering from motor fluctuations and other disabling symptoms.

“We are very enthusiastic about this advance being made available to patients all over the United States.”

NPF is collaborating with AbbVie in the development and delivery of comprehensive training programs for key stakeholders involved in managing treatment with DUOPA.

The pump was approved by the FDA as an orphan drug, a designation granted to products intended for the treatment of rare diseases or conditions affecting fewer than 200,000 patients in the US.

According to AbbVie, the new treatment is the first and only treatment providing 16 continuous hours of carbidopa and levodopa for motor fluctuations in advanced Parkinson’s. In a clinical trial, patients treated with DUOPA reportedly experienced significantly greater reduction in ‘off time’ than patients treated with oral carbidopa-levodopa immediate release tablets.

C. Warren Olanow MD, of the Department of Neurology and Department of Neuroscience, Mount Sinai School of Medicine, and lead investigator of the DUOPA trial, said: “There is an unmet need for treatment options for patients with advanced Parkinson’s disease. As the disease advances, it can be difficult to control motor features.

“In clinical trials, DUOPA was shown to significantly reduce the amount of ‘off’ time people with advanced Parkinson’s disease experienced.”


Go Back

Share this story

Comments


Related articles


WPC Travel Grant

Global update

World Parkinson’s Congress 2016: travel grant applications now open

Financial support available for attendees travelling to WPC 2016

READ MORE
Portland Countdown Eli Pollard

Resources & Tools

World Parkinson Congress: “Nothing else like it anywhere”

Listen to this interview with Eli Pollard, director of the WPC

READ MORE
Sheila Roy (centre)

Perspectives

“There is hope for turning this condition around”

Sheila Roy charts the 'life-changing' effects of new gene therapy

READ MORE